Irbesartan and Amlodipine Combination in Controlling Blood Pressure
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood
Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its
individual constituents administered as monotherapy and placebo.
The secondary objectives are:
- to compare the reduction of mean Seated Systolic Blood Pressure (SeSBP) at the end of 8
weeks from baseline between each FDC, its individual constituents administered as
monotherapy and placebo.
- to compare the reduction of mean SeDBP and SeSBP at 4 weeks from baseline between each
FDC, its individual constituents administered as monotherapy and placebo.